Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor
Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor
复制标题
DOI：
10.1182/blood.v87.10.4129.bloodjournal87104129
复制
发表时间：
1996-05-15
期刊：
影响因子：
20.3
通讯作者：
McKearn, JP
中科院分区：
文献类型：
--
作者：
MacVittie, TJ;Farese, AM;McKearn, JP
Combination cytokine therapy continues to be evaluated in an effort to stimulate multilineage hematopoietic reconstitution after bone marrow myelosuppression. This study evaluated the efficacy of combination therapy with the synthetic interleukin-3 receptor agonist, Synthokine-SC55494, and recombinant methionyl human granulocyte colony-stimulating factor (rhG-CSF) on platelet and neutrophil recovery in nonhuman primates exposed to total body 700 cGy Co-60 gamma radiation. After irradiation on day (d) 0, cohorts of animals subcutaneously received single-agent protocols of either human serum albumin (HSA; every day [QD], 15 mu g/kg/d, n = 10), Synthokine (twice daily [BID], 100 mu g/kg/d, n = 5), rhG-CSF (QD, 10 mu g/kg/d, n = 5), or a combination of Synthokine and rhG-CSF (BID, 100 and 10 mu g/kg/d, respectively, n = 5) for 23 days beginning on d1. Complete blood counts were monitored for 60 days postirradiation and the durations of neutropenia (absolute neutrophil count
